Mirae Asset Global Investments Co. Ltd. Purchases 674 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 76,472 shares of the biopharmaceutical company’s stock after purchasing an additional 674 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.06% of Halozyme Therapeutics worth $2,826,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HALO. Advisory Services Network LLC grew its stake in shares of Halozyme Therapeutics by 50.5% during the 1st quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 303 shares during the period. Belpointe Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 42.0% during the 1st quarter. Belpointe Asset Management LLC now owns 1,238 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 366 shares during the period. Harbour Investments Inc. bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $51,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at about $92,000. Finally, Mendota Financial Group LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $127,000. 97.79% of the stock is currently owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 30,000 shares of company stock valued at $1,196,800 in the last ninety days. Corporate insiders own 2.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on HALO shares. Morgan Stanley cut their price objective on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research note on Tuesday, December 26th. The Goldman Sachs Group cut their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. TD Cowen started coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective for the company. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Stock Down 0.9 %

NASDAQ HALO opened at $38.02 on Thursday. The stock’s 50 day moving average is $39.44 and its 200 day moving average is $37.76. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $45.00. The stock has a market cap of $4.83 billion, a PE ratio of 18.02, a P/E/G ratio of 0.47 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Research analysts predict that Halozyme Therapeutics, Inc. will post 3.33 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.